Yahoo
New episode spotlights the severe burden of Netherton Syndrome in infants and children, reinforcing the need for effective pediatric treatmentsASHBURN, Va., June 26, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the release of a new episode in its NETHERTON NOW video series. The episode features Professor Jemima Mellerio, a recognized author
Yahoo
ASHBURN, Va., June 24, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the Company’s lead asset, QRX003, for the treatment of Netherton Syndrome. The designation reinforces the potential of QRX003 as a therapeutic candidate for a profoundl
Yahoo
By M. Marin NASDAQ:QNRX READ THE FULL QNRX RESEARCH REPORT FDA clears initiation of 2nd NS pivotal whole body clinical study for QRX003, CL-QRX003-002 Quoin Pharmaceuticals (NASDAQ:QNRX), a clinical stage, specialty pharmaceutical company that focuses on developing treatments for rare and orphan diseases, continues to expand clinical activities of QRX003, with several recent FDA approvals to
Yahoo
Quoin Pharmaceuticals (QNRX) said Thursday that it has received US Food and Drug Administration clea
Yahoo
Study CL-QRX003-002 will test whole-body application of QRX003 in conjunction with off-label systemic therapy in approximately 12-15 subjects.Study CL-QRX003-002 complements first whole-body pivotal study, CL-QRX003-003, being led by Dr. Amy Paller at Northwestern University and supported by up to six international sites that are expected to open, where subjects are being tested with QRX003 as monotherapy. Combined data from Studies CL-QRX003-002 and CL-QRX003-003 is anticipated to provide QRX00
Yahoo
Company continues to advance QRX003 in late-stage clinical trials in Netherton Syndrome patients Regulatory milestone provides 10 years of market exclusivity in Europe upon approval ASHBURN, Va., May 20, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces that it has been granted Orphan Drug Designation in Europe by the European Medicines Agency
Current Value
$8.551 Year Return
Current Value
$8.551 Year Return
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| AVO | -15.81% | $846.01M | +20.28% | 0.00% |
| NTZ | -15.17% | $41.64M | -22.22% | 0.00% |
| MGPI | -12.89% | $680.27M | -56.20% | 1.49% |
| KR | -12.39% | $47.17B | +41.48% | 1.81% |
| FIZZ | -11.27% | $4.21B | -14.80% | 0.00% |
| DFDV | -10.44% | $309.70M | +2,106.40% | 0.00% |
| BMY | -9.78% | $96.69B | +17.45% | 5.11% |
| IMKTA | -9.72% | $1.23B | -3.31% | 1.00% |
| UMC | -9.43% | $19.11B | -8.31% | 12.16% |
| HRL | -9.37% | $16.88B | +0.49% | 3.72% |
| BJ | -9.17% | $14.13B | +25.00% | 0.00% |
| HIHO | -8.74% | $7.26M | -20.67% | 4.19% |
| LRN | -8.57% | $6.16B | +105.86% | 0.00% |
| VRTX | -8.34% | $116.11B | -4.56% | 0.00% |
| ADM | -8.16% | $26.16B | -12.36% | 3.70% |
| LITB | -8.13% | $22.07M | -77.41% | 0.00% |
| MO | -8.08% | $97.93B | +26.25% | 6.95% |
| PEP | -7.97% | $185.45B | -17.31% | 4.04% |
| CAG | -7.94% | $10.05B | -25.70% | 6.63% |
| EBAY | -7.93% | $35.08B | +42.91% | 1.48% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| KRRO | 32.92% | $119.92M | -61.43% | 0.00% |
| SPWH | 31.08% | $126.45M | +53.49% | 0.00% |
| PSQH | 25.41% | $97.45M | -38.51% | 0.00% |
| VSEC | 25.24% | $2.67B | +46.83% | 0.31% |
| SNCY | 24.41% | $651.79M | -3.24% | 0.00% |
| SMC | 24.06% | $289.62M | -32.92% | 0.00% |
| LAKE | 23.40% | $129.59M | -39.17% | 0.88% |
| LPTX | 22.85% | $12.28M | -82.47% | 0.00% |
| XNCR | 22.46% | $574.35M | -55.81% | 0.00% |
| FLR | 22.40% | $8.28B | +16.40% | 0.00% |
| OCUL | 22.38% | $1.45B | +36.23% | 0.00% |
| TFIN | 21.61% | $1.45B | -24.52% | 0.00% |
| RDW | 21.56% | $2.18B | +121.56% | 0.00% |
| AAL | 21.56% | $7.60B | +4.25% | 0.00% |
| UAL | 21.52% | $26.14B | +66.08% | 0.00% |
| AUTL | 21.37% | $609.46M | -32.25% | 0.00% |
| GCMG | 21.15% | $577.44M | +16.67% | 3.79% |
| KBR | 21.09% | $6.25B | -24.57% | 1.33% |
| SMR | 21.07% | $4.82B | +230.47% | 0.00% |
| CGNT | 20.60% | $679.27M | +20.87% | 0.00% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -15.97% | $295.67M | 1.43% |
| TAIL | -14.00% | $99.49M | 0.59% |
| BIL | -11.15% | $42.84B | 0.1356% |
| VIXY | -8.54% | $165.58M | 0.85% |
| PSQA | -8.08% | $35.43M | 0.2% |
| BILZ | -7.64% | $827.73M | 0.14% |
| IVOL | -6.56% | $348.25M | 1.02% |
| BOXX | -6.48% | $6.77B | 0.19% |
| FXY | -6.38% | $820.31M | 0.4% |
| TFLO | -6.34% | $6.83B | 0.15% |
| XBIL | -6.20% | $783.84M | 0.15% |
| IYK | -6.08% | $1.45B | 0.4% |
| TBLL | -6.01% | $2.13B | 0.08% |
| CANE | -5.90% | $10.58M | 0.29% |
| WEAT | -5.30% | $117.67M | 0.28% |
| TPMN | -5.08% | $30.70M | 0.65% |
| UNG | -5.07% | $388.31M | 1.06% |
| XLP | -4.52% | $15.86B | 0.09% |
| JMST | -3.83% | $4.06B | 0.18% |
| KXI | -3.82% | $851.26M | 0.41% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BSJP | 22.47% | $853.63M | 0.43% |
| IZRL | 22.31% | $114.42M | 0.49% |
| FDT | 20.82% | $516.54M | 0.8% |
| GREK | 20.22% | $286.31M | 0.57% |
| PREF | 20.04% | $1.22B | 0.55% |
| NUKZ | 19.81% | $370.63M | 0.85% |
| JETS | 19.59% | $811.53M | 0.6% |
| HYLB | 18.98% | $3.97B | 0.05% |
| JAAA | 18.84% | $21.80B | 0.2% |
| PFFV | 18.82% | $304.63M | 0.25% |
| HFND | 18.27% | $27.45M | 1.07% |
| FPEI | 18.14% | $1.60B | 0.85% |
| BSJQ | 18.13% | $1.04B | 0.42% |
| HYS | 18.07% | $1.45B | 0.56% |
| ANGL | 17.81% | $2.94B | 0.25% |
| BOTZ | 17.68% | $2.70B | 0.68% |
| VIDI | 17.64% | $367.61M | 0.61% |
| HYDB | 17.60% | $1.48B | 0.35% |
| GHYB | 17.58% | $92.93M | 0.15% |
| JNK | 17.58% | $7.89B | 0.4% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| CGSM | -0.04% | $708.96M | 0.25% |
| FLIA | 0.06% | $686.06M | 0.25% |
| FXE | -0.09% | $578.76M | 0.4% |
| FLMX | 0.10% | $56.07M | 0.19% |
| GSST | 0.18% | $919.83M | 0.16% |
| LEMB | 0.21% | $343.71M | 0.3% |
| FTSD | -0.28% | $231.68M | 0.25% |
| FXG | -0.33% | $296.19M | 0.63% |
| UDN | -0.42% | $147.49M | 0.78% |
| KRBN | 0.42% | $162.64M | 0.85% |
| UUP | 0.45% | $209.45M | 0.77% |
| SOYB | 0.46% | $26.59M | 0.22% |
| EWW | 0.47% | $1.84B | 0.5% |
| FXC | 0.51% | $93.05M | 0.4% |
| STIP | -0.55% | $12.70B | 0.03% |
| SHV | 0.57% | $20.67B | 0.15% |
| IGOV | 0.58% | $1.21B | 0.35% |
| FLMI | -0.59% | $723.28M | 0.3% |
| UTWO | 0.61% | $379.27M | 0.15% |
| DBA | -0.66% | $792.17M | 0.93% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| GLP | <0.01% | $1.76B | +13.82% | 5.69% |
| SANA | 0.01% | $638.32M | -47.10% | 0.00% |
| HE | 0.01% | $1.93B | +31.26% | 0.00% |
| BRFS | -0.01% | $5.76B | -11.89% | 0.00% |
| SUI | 0.01% | $16.30B | +11.76% | 3.01% |
| WFG | 0.02% | $6.01B | +0.49% | 1.68% |
| BOOM | -0.02% | $175.40M | -39.33% | 0.00% |
| ELAN | -0.02% | $7.17B | +3.00% | 0.00% |
| AFYA | -0.02% | $1.63B | +5.93% | 0.00% |
| MCD | 0.03% | $212.72B | +20.06% | 2.36% |
| MNOV | 0.04% | $62.29M | -9.29% | 0.00% |
| GORV | 0.05% | $27.11M | -91.06% | 0.00% |
| WM | 0.05% | $92.07B | +9.23% | 1.39% |
| UHT | 0.06% | $561.40M | +5.91% | 7.23% |
| OMI | 0.08% | $721.70M | -28.85% | 0.00% |
| BIO | 0.08% | $6.75B | -7.31% | 0.00% |
| HVT | -0.08% | $349.39M | -10.88% | 5.89% |
| SGRY | 0.09% | $2.89B | -4.93% | 0.00% |
| DVA | -0.10% | $11.08B | +5.97% | 0.00% |
| CSGS | 0.11% | $1.91B | +63.12% | 1.89% |
